Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Small cap, high growth healthcare trio


Bookmark and Share

 Jim Oberweis, Jr., money manager and editor of The Oberweis Report, is a long-standing expert in small cap, high growth stocks, trading at reasonable valuations relative to their growth rates.

Here, the advisors looks at a trio of specialty healthcare companies involved in niche markets such as women's health, autoimmune disease and vaccines.

"The Female Health Company (NYSE: FHC) manufactures and markets the femalecondom. This product currently is the only medical device approvedby the FDA under a woman’s control intended to prevent unintended pregnancies and the spread of sexually-transmitted diseases. "The rise of the global HIV/AIDS pandemic, especially in emergingcountries, has increased the need for women to have their ownmeans of disease prevention products. Approximately 80% of thecompany’s customers are public sector agencies including USAID,which distribute the products to areas in need.

"Near-term driversinclude pending FDA approval of its second generation female condom and the recent reauthorization of the EmergencyPlan for AIDS Relief (PEPFAR) which will allocate $48 billion forAIDS prevention and treatment over the next 5 years.

Advertisement
Banner

"In thecompany’s latest reported fourth quarter, sales increased approximately 52% to $7.8 million from $5.2 million in the fourth quarter oflast year. The Female Health Co. reported earnings per share of $.08in the latest reported fourth quarter versus $.04 in the same quarterof last year. 

"Alexion Pharmaceuticals (NASDAQ: ALXN) is a biopharmaceutical company focused on the development of therapeutic products for the treatment of severe diseases including cardiovascular and autoimmunedisorders and cancer. 

"The majority of the company’s current salescome from their Soliris product used to treat a rare blood disorderreferred to as PNH (paroxysmal nocturnal hemoglobinuria). PNH isa rare, acquired (not inherited) blood disorder.

"PNH  causes anindividual’s immune system to destroy its own red blood cells (calledhemolysis), resulting in life-threatening thrombosis, recurrent pain,kidney disease, disabling fatigue, and impaired quality of life.

"Solirisis the only available therapy to block hemolysis in patients withPNH. Soliris was discovered, developed and marketed exclusivelyby Alexion following FDA approval in the US in March 2007.

"InJune of 2007, the European Commission (EU) approved Soliris forthe treatment of patients with PNH in 29 countries. Today roughly67% of the company’s revenues are derived in the US with theremainder coming from Europe.

"In the company’s latest reportedthird quarter, sales increased approximately 250% to $76.5 millionfrom $21.8 million in the third quarter of last year. Alexion Pharmaceuticals reported earnings per share of $.23 in the latest reportedthird quarter versus a loss in the same quarter of last year. 

"Akorn (NASDAQ: AKRX) develops ophthalmic and injectable pharmaceutical products. One of the company’s main growth drivers is its genericTetanus Diphtheria vaccine, which the company estimates has already taken 25% of the market share versus its brand-name competitor in just a little over a year.

"Other near-term developmentsinclude the October 2008 launch of a premium ophthalmic anesthetic, Akten Gel 3.5%, which can be used for a variety of procedures including cataract surgery, retina surgery, and other miscellaneous ocular procedures.

"In the company’s latest reported thirdquarter, sales increased approximately 102% to $31.9 million from$15.8 million in the third quarter of last year.  Akorn reported earnings per share of $.03 versus a loss in the same quarter of last year. 

"Clients of Oberweis Asset Management own approximately 600,000 shares of The Female Health Co., approximately 34,000 shares of Alexion and 850,000 shares of Akom.We consider the shares of these companies appropriate for risk oriented investors."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary